In a world where a drug takes years and billions of dollars to develop, just one in 20 candidates makes it to market. Daphne Koller [7] is betting artificial intelligence can change that dynamic.

Twenty years ago, when she first started using artificial intelligence to venture into medicine and biology, Koller was stymied by a lack of data. There wasn’t enough of it and what there was, was often not well suited to the problems she wanted to solve. Fast-forward 20 years, however, and both the quantity and quality of data, and the tools for studying biology, have advanced so dramatically that the adjunct professor of computer science at Stanford founded a company, insitro, that uses machine learning (a subspecialty of ​artificial intelligence) to explore the causes and potential treatments for some very serious diseases.

She tells bioengineer Russ Altman [8] about the lessons she’s learned along the way, and the challenges and rewards of getting diverse teams of experts from many fields to speak the same language. It’s all on this episode of Stanford Engineering’s The Future of Everything podcast. Listen here, and subscribe to the podcast here [9].

Daphne Koller [7], adjunct professor of computer science

Russ Altman [10], the Kenneth Fong Professor of Bioengineering, of genetics, of medicine (general medical discipline), of biomedical data science and, by courtesy, of computer science